With regard to the health care, life science, and biotech side, we notice that a lot of our competitors over the last 10 years have taken advantage of the U.S. SBIR grants. We've always been quite envious of that because, unlike you, Sue, I raised VC for my very first biotech company. On this one we raised it all—angel, strategic, bypass, VC—every one. It would have been helpful in the early days if there was some sort of SBIR-type program.
On December 7th, 2017. See this statement in context.